Amgen data on drug with ‘undruggable’ target at ASCO gets muted reception

Published on:

The company announced poster presentations for the ASCO virtual meeting on AMG 510, its KRAS G12c inhibitor, in patients with colorectal cancer and a broad range of cancers. But an analyst called the drug “unimpressive” outside of non-small cell lung cancer.

Read more    Source:

Leave a Reply